Presentation and outcomes with clinically apparent interferon beta hepatotoxicity

Digestive Diseases and Sciences

Volumn 58, Issue 6, 2013, Pages 1766-1775

  Fontana, Robert J ^a   Hayashi, Paul ^b   Bonkovsky, Herbert L ^b,c   Kleiner, David E ^d   Kochhar, Sweta ^a   Gu, Jiezhun ^e   Ghabril, Marwan ^f  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CAROLINAS MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Acute liver failure; Biologic response modifiers; Drug induced liver injury; Liver biopsy; Multiple sclerosis

Indexed keywords

ALANINE AMINOTRANSFERASE; AUTOANTIBODY; BETA INTERFERON; BETA1A INTERFERON; CLONAZEPAM; CODEINE; EZETIMIBE; HYDROCHLOROTHIAZIDE; LISINOPRIL; MACROGOL; OXAPROZIN; SIMVASTATIN; SMOOTH MUSCLE ANTIBODY; TIZANIDINE;

ACUTE LIVER FAILURE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIPOLAR DISORDER; CAUCASIAN; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONSTIPATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; EPIDEMIOLOGY; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERTENSION; JAUNDICE; LIVER CELL DAMAGE; LIVER HISTOLOGY; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOCYTE; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; NAUSEA; OUTCOME ASSESSMENT; PLASMA CELL; PRIORITY JOURNAL; REGISTER; SELF CONCEPT; SIDE EFFECT;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MIDDLE AGED; MULTIPLE SCLEROSIS; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 84879505702     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2553-1     Document Type: Article

References (39)

1. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129.
2. Weiner HL. Multiple sclerosis is an inflammatory T-cell mediated autoimmune disease. Arch Neurol. 2004;61:1613.
3. Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized controlled trial. Neurology. 2003;60:44.
4. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63:1779.
5. Francis GS, Grumser Y, Alteri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf. 2003;26:815-827.
6. Durelli L, Ferrero B, Oggero A, Betaferon safety trial (BEST) study group, et al. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology. 2001;57:1363-1370.
7. Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Multiple Scler. 2004;10:298-301.
8. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: comparison between the 3 products. Neurology. 2004;62:628-631.
9. Yoshida EM, Rasmussen SL, Steinbrecher UP, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology. 2001;56:1415.
10. Fontana RJ, Seeff LB, Andrade RJ, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology. 2010;52:730-742.
11. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-954.
12. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology. 2008;135:1924-1934.
13. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Rationale, design and conduct of the drug induced liver injury network prospective study. Drug Saf. 2009;32:55-68.
14. Rochon J, Protiva P, Seeff LB, et al. Reliability of the RUCAM for assessing causality in drug-induced liver injury. Hepatology. 2008;48:1175-1183.
15. Kethu SR, Rukkannagari S, Lansford CL. Oxaprozin-induced symptomatic hepatotoxicity. Ann Pharmacother. 1999;33(942):4.
16. Grieco A, Montalto M, Vero V, et al. Severe acute hepatitis after resumption of interferon-beta therapy: a word of caution. Am J Gastroenterol. 2007;102:1504-1506.
17. Durelli L, Bongioanni MR, Ferrero B, et al. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology. 1998;50:570-571.
18. Wallack EM, Callon R. Liver injury associated with the B-interferons for MS. Neurology. 2004;63:1142-1143.
19. Byrnes V, Afdhal N, Challies T, et al. Drug-induced liver injury secondary to interferon-beta in multiple sclerosis. Ann Hepatol. 2006;5:56-59.
20. Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol. 2002;97:767-768.
21. Pietrosi G, Mandala L, Vizzini GB, et al. Fulminant hepatic failure and autoimmune disorders in patient with multiple sclerosis on interferon beta-1a: a fatal combination. Transpl Int. 2008;21:502-504.
22. Montero JL, Cerezo A, Fraga E, et al. Acute liver failure in a patient with multiple sclerosis treated with interferon-beta. Multiple Scler. 2007;13:820.
23. Pulicken M, Koteish A, DeBusk K, et al. Unmasking of autoimmune hepatitis in a patient with MS following interferon beta therapy. Neurology. 2006;66:1954-1955.
24. Nunez O, de Andres C, Alverez E, et al. Autoimmune hepatitis in patients with a diagnosis of multiple sclerosis. Gastroenterol Hepatol. 2004;27:521-524.
25. Olek MJ. Treatment of relapsing-remitting multiple sclerosis. http://www.uptodate.com/contents/search. Accessed 2 December 2012.
26. Chan S, Kingwell E, Oger J, et al. High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study. Multiple Scler. 2011;17:361-367.
27. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520.
28. Sundberg R, Toren K, Franklin KA, et al. Asthma in men and women: treatment adherence, anxiety, and quality of sleep. Resp Med. 2010;104:337-344.
29. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 2005;129:512-521.
30. Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology. 2010;52:2065-2076.
31. Itoh S, Marutani K, Matsuo S. Changes in ultrastructure of hepatocytes and liver test results before, during and after treatment with interferon-beta in patients with HBeAg positive chronic active hepatitis. Dig Dis Sci. 1992;37:12607.
32. Careli M, Porras MC, Rizzardini M, et al. Modulation of constitutive and inducible hepatic cytochrome P-450 by interferon beta in mice. J Hepatol. 1996;24:230-237.
33. Farnsworth A, Flaman A, Prasad SS, et al. Acetaminophen modulates the transcriptional response to recombinant interferon-beta. POLS One. 2010;5:11031.
34. Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med. 1992;116:51-53.
35. Te HS, Koukoulis G, Ganger DR. Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut. 1997;41:269-271.
36. Singh R, Nair S, Farr G, et al. Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol. 2002;97:2670-2673.
37. Speciale L, Saresella M, Caputo D, et al. Serum auto-antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J Neurovirol. 2000;6:S57-S61.
38. Polman CH, Kappos L, Dahlke F, the European Study Group on Interferon-Beta 1b in SPMS, et al. Interferon beta-1b treatment does not induce autoantibodies. Neurology. 2005;64:996-1000.
39. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum. 1997;40:1601. Diseases